Japanese Journal of Clinical Oncology 30:131-136 (2000)
© 2000 Foundation for Promotion of Cancer Research
Early Results of LH-RH Agonist Treatment with or without Chlormadinone Acetate for Hormone Therapy of Naive Localized or Locally Advanced Prostate Cancer: A Prospective and Randomized Study
Department of Urology, 1Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, 2The University of Tokyo, Tokyo, 3Nihon University, Tokyo, 4Toranomon Hospital, Tokyo, 5Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, 6Nara Medical University, Kashiwara, Nara, 7Okayama University, Okayama, 8Department of Epidemiology and Biostatistics, School of Health Sciences and Nursing, The University of Tokyo, Tokyo and 9Fujieda Municipal General Hospital, Fujieda, Shizuoka, Japan
Background: The majority of patients with localized and some cases of locally advanced prostate cancer undergo radical prostatectomy. However, radical prostatectomy cannot always be selected for those patients. In this situation, primary hormone therapy is an alternative treatment option. We have designed a prospective randomized study of the effects of primary hormone therapy for such patients.
Methods: A total of 151 patients with T1b, T1c, T2a, T2b or T3a prostate cancer who were not scheduled for radical prostatectomy were enrolled into this study. Patients were randomly allocated into two groups; Group I received luteinizing hormone-releasing hormone (LH-RH) agonist monotherapy (leuprorelin acetate depot, 3.75 mg monthly) and Group II received LH-RH agonist in combination with chlormadinone acetate (100 mg/day). Effects on serum prostate-specific antigen level, progression-free survival and survival were observed for 2 years.
Results: The reasons why radical prostatectomy was not scheduled were poor risk for surgery (38%), patient’s wish (32%) and physician’s recommendation (30%). After 12 weeks of treatment, 49% of the patients in both groups showed a complete response (CR). Of the patients showing a partial response (PR) after 12 weeks of treatment, 25% in Group I and 52% in Group II improved to CR 1 year later (p < 0.05). Group II showed a longer progression-free survival (p < 0.05). Progression-free survival rates were 62% (Group I) and 91% (Group II) in T2b patients and 43% (Group I) and 73% (Group II) in T3 patients. Only one patient in each group died from prostate cancer.
Conclusions: Early primary hormone therapy is a reasonable treatment option for localized or locally advanced prostate cancer patients if radical prostatectomy was not scheduled. Chlormadinone acetate showed an additive effect with LH-RH agonist, at least in 2 years’ observation.
+ For reprints and all correspondence: Hideyuki Akaza, Department of Urology, Institute of Clinical Medicine, University of Tsukuba, 1–1–1 Tennoudai, Tsukuba, Ibaraki 305-0006, Japan. E-mail: akazah@md.tsukuba.ac.jpAbbreviations: LH-RH, luteinizing hormone-releasing hormone; PSA, prostate-specific antigen; CR, complete response; PR, partial response; TRUS, transrectal ultrasonography; QOL, quality of life; MAB, maximum androgen blockade; CT, computed tomography; CMA, chlormadinone acetate; NC, no change; PD, progressive disease
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. R. Cooperberg, D. P. Lubeck, M. V. Meng, S. S. Mehta, and P. R. Carroll The Changing Face of Low-Risk Prostate Cancer: Trends in Clinical Presentation and Primary Management J. Clin. Oncol., June 1, 2004; 22(11): 2141 - 2149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Cooperberg, G. D. Grossfeld, D. P. Lubeck, and P. R. Carroll National Practice Patterns and Time Trends in Androgen Ablation for Localized Prostate Cancer J Natl Cancer Inst, July 2, 2003; 95(13): 981 - 989. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ozono, E. Okajima, A. Yamaguchi, M. Yoshikawa, A. Iwai, A. Moriya, K. Yoshida, S. Samma, Y. Maruyama, Y. Hirao, et al. A Prospective Randomized Multicenter Study of Chlormadinone Acetate versus Flutamide in Total Androgen Blockade for Prostate Cancer Jpn. J. Clin. Oncol., September 1, 2000; 30(9): 389 - 396. [Abstract] [Full Text] [PDF]
|
|